YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine....
Hence then, the article about gc biopharma s recombinant anthrax vaccine barythrax demonstrates safety and immunogenicity in phase 2 data published in vaccine was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine' )
Also on site :
- Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
- Reported tornado rips roofs off multiple homes in central Illinois
- Heidi Klum ditches bikini top to cozy up to husband Tom Kaulitz during St. Barths vacation